Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience

Bone Marrow Transplantation volume 51, pages 1307–1312 (2016)Cite this article

Subjects

Abstract

Relapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and 26 days. Cumulative incidences of grades II–IV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P=0.015) and OS (86% vs 46%; P=0.044). Our findings further confirm prior reports using HAPLO-RIC in advanced HL in a multicenter approach employing an IV busulfan-based conditioning regimen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D et al. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol 2014; 166: 34–49.

    Article  CAS  Google Scholar 

  2. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN . Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant 2014; 49: 599–606.

    Article  CAS  Google Scholar 

  3. Sureda A, Domenech E, Schmitz N, Dreger P . Lymphoma Working Party of the European Group for Stem Cell Transplantation. The role of allogeneic stem cell transplantation in Hodgkin's lymphoma. Curr Treat Options Oncol 2014; 15: 238–247.

    Article  Google Scholar 

  4. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.

    Article  Google Scholar 

  5. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    Article  CAS  Google Scholar 

  6. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  Google Scholar 

  7. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  Google Scholar 

  8. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310–317.

    Article  Google Scholar 

  9. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1934–1941.

    Article  Google Scholar 

  10. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279–1287.

    Article  Google Scholar 

  11. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2014; 49: 190–194.

    Article  CAS  Google Scholar 

  12. Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B et al. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 2014; 49: 1475–1480.

    Article  CAS  Google Scholar 

  13. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  Google Scholar 

  14. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3671.

    Article  CAS  Google Scholar 

  15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  16. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  17. Buño I, Nava P, Simón A, González-Rivera M, Jiménez JL, Balsalobre P et al. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 2005; 90: 1373–1379.

    PubMed  Google Scholar 

  18. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  Google Scholar 

  19. Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, Kwon M, Serrano D et al. Busulfan based reduced intensity conditioning regimen for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant 2015; 50: S6 (O-008).

    Article  Google Scholar 

  20. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

    Article  CAS  Google Scholar 

  21. Santos GW . Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant 1989; 4: 236–239.

    PubMed  Google Scholar 

  22. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.

    Article  Google Scholar 

  23. Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724–729.

    Article  Google Scholar 

  24. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.

    Article  CAS  Google Scholar 

  25. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014; 20: 314–318.

    Article  CAS  Google Scholar 

  26. Ghiso A, Raiola AM, Gualandi F, Dominietto A, Varaldo R, Van Lint MT et al. DLI after BMT with post-transplant DLI. Bone Marrow Transplant 2015; 50: 56–61.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Ministry of Economy and Competitiveness ISCIII-FIS grants PI11/00708, PI14/01731 and RD12/0036/0061, co-financed by ERDF (FEDER) Funds from the European Commission, ‘A way of making Europe’, as well as grants from Asociación Española Contra el Cáncer (AECC) and Fundación Mutua Madrileña (FMM).

Author information

Authors and Affiliations

  1. Servicio de Hematología, Unidad de Trasplante Hematopoyético, HGU Gregorio Marañón, Madrid, Spain

    J Gayoso, P Balsalobre, M Kwon, D Serrano, C Pascual, I Buño & J L Díez-Martín

  2. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

    J Gayoso, P Balsalobre, M Kwon, D Serrano, C Pascual, I Buño & J L Díez-Martín

  3. Hospital Regional Universitario, Málaga, Spain

    M J Pascual

  4. HGU Morales Meseguer, Murcia, Spain

    C Castilla-Llorente & I Heras

  5. Hospital Clínico Universitario, Salamanca, Spain

    L López-Corral

  6. Hospital Clínico Universitario, Valencia, Spain

    J L Piñana

  7. Hospital Universitario Ramón y Cajal, Madrid, Spain

    P Herrera

  8. ICO Badalona, Badalona, Spain

    C Ferrá

  9. Hospital Universitario La Fé, Valencia, Spain

    P Montesinos

  10. Complejo Hospitalario de Navarra, Pamplona, Spain

    A Zabalza

  11. Hospital Universitario Son Espases, Palma de Mallorca, Spain

    L Bento

  12. Hospital Universitario La Princesa, Madrid, Spain

    A Figuera

Authors
  1. J Gayoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Balsalobre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M J Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Castilla-Llorente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L López-Corral
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L Piñana
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Herrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Ferrá
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I Heras
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P Montesinos
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Zabalza
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. L Bento
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Figuera
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. I Buño
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J L Díez-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of GETH (Spanish Group for Hematopoietic Transplantation)

Corresponding author

Correspondence to J Gayoso.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gayoso, J., Balsalobre, P., Pascual, M. et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant 51, 1307–1312 (2016). https://doi.org/10.1038/bmt.2016.115

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.115

This article is cited by

Search

Advanced search

Quick links